CALIFORNIA RETINA CONSULTANTS

The HELIOS trial revealed OTX-TKI was well-tolerated with no serious adverse events, with all diabetic retinopathy severity score improvements occurring in the treatment arm and all worsening in the sham arm.

Interim 48-week data from the Phase 1 HELIOS trial demonstrates that a single injection of OTX-TKI (sustained-release axitinib implant) prevented disease progression in patients with moderately severe to severe non-proliferative diabetic retinopathy.